Table 2.
Comparison of microRNA polymorphic genotype frequencies in controls and RPL patients.
| Characteristics | Controls n = 227 | PL ≥ 2 n = 388 | AOR (95% CI) a | p b | FDR-p c | PL ≥ 3 n = 206 | AOR (95% CI) a | p b | FDR-p c |
|---|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | |||||||
| miR-604A>G | |||||||||
| AA | 73 (32.2) | 171 (44.1) | 1.000 (reference) | 86 (41.7) | 1.000 (reference) | ||||
| AG | 115 (50.7) | 173 (44.6) | 0.640 (0.445–0.920) | 0.016 | 0.061 | 95 (46.1) | 0.686 (0.452–1.04) | 0.076 | 0.126 |
| GG | 39 (17.2) | 44 (11.3) | 0.496 (0.296–0.832) | 0.008 | 0.024 | 25 (12.1) | 0.532 (0.292–0.970) | 0.04 | 0.12 |
| Dominant (AA vs. AG + GG) | 0.606 (0.429–0.856) | 0.005 | 0.025 | 0.650 (0.438–0.965) | 0.033 | 0.055 | |||
| Recessive (AA + AG vs. GG) | 0.621 (0.389–0.992) | 0.046 | 0.138 | 0.646 (0.374–1.117) | 0.118 | 0.276 | |||
| miR-608C>G | |||||||||
| CC | 48 (21.1) | 93 (24.0) | 1.000 (reference) | 51 (24.8) | 1.000 (reference) | ||||
| CG | 109 (48.0) | 189 (48.7) | 0.885 (0.581–1.349) | 0.57 | 0.57 | 103 (50.0) | 0.867 (0.536–1.401) | 0.559 | 0.559 |
| GG | 70 (30.8) | 106 (27.3) | 0.789 (0.497–1.252) | 0.314 | 0.471 | 52 (25.2) | 0.702 (0.411–1.199) | 0.195 | 0.292 |
| Dominant (CC vs. CG + GG) | 0.850 (0.572–1.261) | 0.419 | 0.419 | 0.805 (0.513–1.263) | 0.345 | 0.345 | |||
| Recessive (CC + CG vs. GG) | 0.847 (0.591–1.214) | 0.366 | 0.549 | 0.751 (0.492–1.146) | 0.184 | 0.276 | |||
| miR-631I/D | |||||||||
| II | 204 (89.9) | 357 (92.0) | 1.000 (reference) | 193 (93.7) | 1.000 (reference) | ||||
| ID | 23 (10.1) | 31 (8.0) | 0.778 (0.441–1.372) | 0.385 | 0.481 | 13 (6.3) | 0.577 (0.283–1.178) | 0.131 | 0.163 |
| DD | 0 (0.0) | 0 (0.0) | N/A | N/A | N/A | 0 (0.0) | N/A | N/A | N/A |
| Dominant (II vs. ID + DD) | 0.778 (0.441–1.372) | 0.385 | 0.419 | 0.577 (0.283–1.178) | 0.131 | 0.163 | |||
| Recessive (II + ID vs. DD) | N/A | N/A | N/A | N/A | N/A | N/A | |||
| miR-938G>A | |||||||||
| GG | 215 (94.7) | 380 (97.9) | 1.000 (reference) | 204 (99.0) | 1.000 (reference) | ||||
| GA | 12 (5.3) | 8 (2.1) | 0.375 (0.151–0.933) | 0.035 | 0.061 | 2 (1.0) | 0.179 (0.040–0.811) | 0.026 | 0.087 |
| AA | 0 (0.0) | 0 (0.0) | N/A | N/A | N/A | 0 (0.0) | N/A | N/A | N/A |
| Dominant (CC vs. CT + TT) | 0.375 (0.151–0.933) | 0.035 | 0.061 | 0.179 (0.040–0.811) | 0.026 | 0.055 | |||
| Recessive (CC + CT vs. TT) | N/A | N/A | N/A | N/A | N/A | N/A | |||
| miR-1302-3C>T | |||||||||
| CC | 212 (84.1) | 349 (89.9) | 1.000 (reference) | 188 (91.3) | 1.000 (reference) | ||||
| CT | 14 (15.5) | 37 (9.5) | 0.596 (0366–0.969 ) | 0.037 | 0.061 | 18 (8.7) | 0.517 (0.280–0.955) | 0.035 | 0.087 |
| TT | 1 (0.4) | 2 (0.5) | 1.101 (0.099–12.228) | 0.937 | 0.937 | 0 (0.0) | N/A | 0.994 | 0.994 |
| Dominant (CC vs. CT + TT) | 0.596 (0.366–0.969) | 0.037 | 0.061 | 0.502 (0.273–0.952) | 0.027 | 0.055 | |||
| Recessive (CC + CT vs. TT) | 1.177 (0.106–13.059) | 0.894 | 0.894 | N/A | 0.994 | 0.994 | |||
Abbreviations: RPL, recurrent pregnancy loss; AOR, adjusted odds ratio; CI, confidence interval. a Adjusted for age. b Fisher’s exact test. c False-positive discovery rate (FDR)-adjusted p-value. Bold numbers indicate significant p-values. N/A: not applicable